MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-118 CLINICAL STUDY: New PPARg covalent partial agonist in healthy volunteers

Navarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase 1 clinical trial of MBF-118, a novel covalent partial agonist of PPARg nuclear receptor. The objectives of the clinical trial are the preliminary evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of MBF-118 after oral intake in healthy volunteers.

The release as fetched from its publisher. medibiofarma.com ↗